Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 19/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 19/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318549 | 0.88 | AURKA (0.74) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4320221 | 0.84 | AURKA (0.79) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4309256 | 0.81 | AURKA (0.74) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL14492827 | 0.80 | AURKA (0.81) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4311938 | 0.80 | AURKA (1.00) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4319404 | 0.79 | AURKA (1.00) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4953871 | 0.79 | AURKA (0.80) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4307090 | 0.77 | AURKA (1.00) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4310617 | 0.76 | AURKA (1.00) | AURKAAURKBLYNIGF1RMET | |
| SCHEMBL4312350 | 0.75 | AURKA (1.00) | AURKAAURKBLYNIGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885LYN 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.